Holen Sie sich die Stockscreener-App
89.27
0.04%
-0.04
Handel nachbörslich:
89.80
0.53
+0.59%
Schlusskurs vom Vortag:
$89.31
Offen:
$89
24-Stunden-Volumen:
1.57M
Relative Volume:
1.29
Marktkapitalisierung:
$22.44B
Einnahmen:
$3.32B
Nettoeinkommen (Verlust:
$-1.26B
KGV:
-17.07
EPS:
-5.2311
Netto-Cashflow:
$289.80M
1W Leistung:
-2.11%
1M Leistung:
-18.95%
6M Leistung:
-7.22%
1J Leistung:
-7.23%
1-Tages-Spanne:
$87.16
$89.62
1-Wochen-Bereich:
$87.16
$95.14
52-Wochen-Spanne:
$79.52
$124.00
Biontech Se Adr Stock (BNTX) Company Profile
Compare BNTX vs VRTX, REGN, ALNY, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BNTX
Biontech Se Adr
|
89.27 | 22.44B | 3.32B | -1.26B | 289.80M | -5.2311 |
VRTX
Vertex Pharmaceuticals Inc
|
454.00 | 115.33B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
732.87 | 77.48B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
312.17 | 41.40B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
663.93 | 41.09B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
275.28 | 30.56B | 5.36B | 287.73M | 924.18M | 2.5229 |
Biontech Se Adr Stock (BNTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-02 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2026-01-16 | Hochstufung | Goldman | Neutral → Buy |
| 2025-06-05 | Bestätigt | H.C. Wainwright | Buy |
| 2025-05-29 | Eingeleitet | Goldman | Neutral |
| 2025-03-13 | Eingeleitet | Citigroup | Buy |
| 2025-01-10 | Eingeleitet | Truist | Buy |
| 2024-12-11 | Eingeleitet | Wells Fargo | Overweight |
| 2024-12-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2024-11-19 | Eingeleitet | Berenberg | Buy |
| 2024-11-19 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-11-08 | Hochstufung | Goldman | Neutral → Buy |
| 2024-09-24 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-09-17 | Hochstufung | Jefferies | Hold → Buy |
| 2024-09-16 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2024-08-07 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-08-02 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-05-14 | Eingeleitet | Evercore ISI | In-line |
| 2024-02-23 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-01-05 | Eingeleitet | Oppenheimer | Perform |
| 2023-12-01 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-10-16 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-05-17 | Hochstufung | Redburn | Neutral → Buy |
| 2022-12-15 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-08-17 | Eingeleitet | Cowen | Market Perform |
| 2022-07-13 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-07-06 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-02-01 | Hochstufung | Redburn | Sell → Neutral |
| 2021-12-16 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-11-10 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2021-10-22 | Eingeleitet | Deutsche Bank | Hold |
| 2021-10-07 | Eingeleitet | Jefferies | Hold |
| 2021-08-11 | Hochstufung | Bryan Garnier | Neutral → Buy |
| 2021-07-19 | Fortgesetzt | Wolfe Research | Outperform |
| 2021-06-16 | Herabstufung | Redburn | Neutral → Sell |
| 2021-05-18 | Eingeleitet | Goldman | Neutral |
| 2021-05-11 | Herabstufung | Bryan Garnier | Buy → Neutral |
| 2020-12-01 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-08-03 | Fortgesetzt | Berenberg | Buy |
| 2020-07-21 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-06-30 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-05-19 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-04-28 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2020-03-18 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-03-09 | Eingeleitet | H.C. Wainwright | Neutral |
| 2020-01-24 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-01-22 | Herabstufung | UBS | Buy → Neutral |
| 2019-11-05 | Eingeleitet | Wolfe Research | Outperform |
| 2019-11-04 | Eingeleitet | Berenberg | Buy |
| 2019-11-04 | Eingeleitet | BofA/Merrill | Buy |
| 2019-11-04 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-11-04 | Eingeleitet | JP Morgan | Overweight |
| 2019-11-04 | Eingeleitet | SVB Leerink | Outperform |
| 2019-11-04 | Eingeleitet | UBS | Buy |
Alle ansehen
Biontech Se Adr Aktie (BNTX) Neueste Nachrichten
AKT I: „ICI VARSOVIE” [c66293] - fathomjournal.org
BioNTech's Oncology Pivot Accelerates Amid Leadership Transition and €17B Cash Reserve - AD HOC NEWS
Hudson Bay Capital Management LP Acquires 55,004 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech Stock Forecast | Co-Founders Plan Departure - Capital.com
Groupama Asset Managment Trims Holdings in BioNTech SE Sponsored ADR $BNTX - MarketBeat
BNTX Stock Price, Quote & Chart | BIONTECH SE-ADR (NASDAQ:BNTX) - ChartMill
BioNTech stock plunges as founders leave. Should you buy the dip in BNTX here? - MSN
Long Focus Capital Management LLC Has $39.22 Million Stock Holdings in BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
BioNTech a Takeover Target? What's Happening at CHAR Technologies and Steyr Motors? - news.financial
symbol__ Stock Quote Price and Forecast - CNN
125,000 Shares in BioNTech SE Sponsored ADR $BNTX Purchased by Ghisallo Capital Management LLC - MarketBeat
BioNTech SE Sponsored ADR $BNTX Shares Acquired by Dodge & Cox - MarketBeat
BioNTech SE Stock (ISIN: US09075V1026) Faces Pressure After Leadership Exodus and Earnings Miss - AD HOC NEWS
BNP Paribas Financial Markets Lowers Stock Holdings in BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech's Promising Oncology Pipeline Is Now in Late-Stage Development - Morningstar
BioNTech (NASDAQ:BNTX) Sees Large Volume IncreaseHere's What Happened - MarketBeat
Serve Robotics Posts Upbeat Q4 Results, Joins Auna, Acacia Research And Other Big Stocks Moving Higher On Wednesday - Benzinga
BMO cuts BioNTech stock price target on CEO departure plans - Investing.com
BioNTech SE Sponsored ADR $BNTX Shares Sold by Capital International Inc. CA - MarketBeat
Form 144 BioNTech SE For: 11 March - Investing.com
BioNTech tumbles over 19% on fourth quarter earnings miss - Investing.com
Oppenheimer maintains BioNTech stock rating amid leadership exit - Investing.com
BioNTech stock price target lowered to $167 by Clear Street - Investing.com
BioNTech Stock Plunges as Founders Leave. Should You Buy the Dip in BNTX Here? - inkl
BioNTech Stock Tanks As Outlook, Founder Exit Rattle Bulls - Benzinga
Truist reiterates Buy on BioNTech stock after revenue guidance - Investing.com
BofA cuts BioNTech stock price target on leadership transition - Investing.com South Africa
Micron and BioNTech among market cap stock movers on Tuesday By Investing.com - Investing.com India
Micron and BioNTech among market cap stock movers on Tuesday - Investing.com
BioNTech (NASDAQ:BNTX) Hits New 1-Year LowHere's What Happened - MarketBeat
BioNTech Q4 Earnings Call Highlights - Yahoo Finance
BioNTech co-founding couple Sahin and Tuereci leaving to create new company - The Globe and Mail
FreightCar America Posts Downbeat Q4 Results, Joins BioNTech, PROG Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
BioNTech founders to establish new mRNA company, step down by year-end - Investing.com
BioNTech earnings loom with revenue dive, pipeline progress in focus - Investing.com
BioNTech SE Sponsored ADR $BNTX Shares Acquired by Victory Capital Management Inc. - MarketBeat
BioNTech Expands Oncology Pipeline With New First‑in‑Human BNT3214 Cancer Trial - The Globe and Mail
Is BioNTech SE (BNTX) A Good Stock To Buy Now? - Finviz
BioNTech Expands Infectious Disease Pipeline With New Mpox mRNA Vaccine Trial in Africa - TipRanks
Sobre Bruno Hansmann - eToro
Primecap Management Co. CA Sells 130,700 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
Analysts’ Top Healthcare Picks: Ascendis Pharma (ASND), BioNTech SE (BNTX) - The Globe and Mail
BioNTech Escalates mRNA Legal Battle with Moderna Over Next-Gen Vaccine () - aktiencheck.de
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
BioNTech’s New HIV Antibody Trial Adds Depth to BNTX’s Long-Term Pipeline Story - TipRanks
BioNTech SE (BNTX) Rallying on Solid Oncology Strategy - Finviz
BioNTech SE Sponsored ADR $BNTX Shares Sold by CenterBook Partners LP - MarketBeat
BioNTech's Strategic Pivot: Key Catalysts on the 2026 Horizon () - aktiencheck.de
BMY Up 7.6% Post Q4 Earnings: Should You Buy, Sell or Hold the Stock? - Finviz
Pfizer and BioNTech Pause modRNA Shingles Ambitions - TipRanks
Finanzdaten der Biontech Se Adr-Aktie (BNTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.89%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):